SI0800536T1 - Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5 - Google Patents

Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5

Info

Publication number
SI0800536T1
SI0800536T1 SI9530729T SI9530729T SI0800536T1 SI 0800536 T1 SI0800536 T1 SI 0800536T1 SI 9530729 T SI9530729 T SI 9530729T SI 9530729 T SI9530729 T SI 9530729T SI 0800536 T1 SI0800536 T1 SI 0800536T1
Authority
SI
Slovenia
Prior art keywords
recombinant
treatment
mediated disorders
antagonists useful
antagonists
Prior art date
Application number
SI9530729T
Other languages
English (en)
Inventor
Robert S Ames
Edward Robert Appelbaum
Irwin M Chaiken
Richard M Cook
Mitchell Stuart Gross
Stephen Dudley Holmes
Lynette Jane Mcmillan
Timothy Wayne Theisen
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/467,420 external-priority patent/US5683892A/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Priority claimed from EP95944692A external-priority patent/EP0800536B1/en
Publication of SI0800536T1 publication Critical patent/SI0800536T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI9530729T 1994-12-23 1995-12-22 Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5 SI0800536T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
EP95944692A EP0800536B1 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number Publication Date
SI0800536T1 true SI0800536T1 (sl) 2007-04-30

Family

ID=37575034

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530729T SI0800536T1 (sl) 1994-12-23 1995-12-22 Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5

Country Status (1)

Country Link
SI (1) SI0800536T1 (sl)

Similar Documents

Publication Publication Date Title
HUS1500070I1 (hu) IL-5-Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták
AP9600782A0 (en) Recombinant il,4 antibodies useful in treatment of il,4 mediated disorders
HUP0200502A3 (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
HUP0103114A3 (en) Apolipoprotein a-1 agonists and their use to treat dyslipidemic disorders
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
IL112860A0 (en) Recombinant viruses their preparation and their therapeutic uses
EP1005345A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC ASTHMA AND OTHER CONDITIONS USING DESCARBOETHOXYLORATADINE
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HK1015280A1 (en) Use of epinastine in the treatment of pain
EP0748219A4 (en) COMPOUNDS FOR TREATING DISEASES RELATED TO VASCULOGENESE AND / OR ANGIOGENESE
ZA946875B (en) Recombinant il4 antibodies useful in treatment of il4 mediated disorders
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
HUP0000873A3 (en) The use of levobupivacaine in facial surgery
GB2317109B (en) A therapeutic composition for the treatment and repair of connective tissue in mammals
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA971419B (en) Macrocyclic peptides useful in the treatment of thrombin related disorders
SI0800536T1 (sl) Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5
IL127464A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
EP0846701A4 (en) RECOMBINANT CONGLUTININ AND PROCESS FOR ITS PRODUCTION
GB2263549B (en) Improvements in and relating to proximity switches
ZA9510824B (en) Novel piperdine derivatives processes for their preparation and their use in treating csn disorders
SI0833839T1 (sl) Peptidilni heterocikli, uporabni pri zdravljenju motenj, povezanih s trombinom